VAKCINA

Forty-seven coronavirus patients are currently on ECMO machines, which replace the function of the heart and lungs and are used in the most serious cases where lives are in danger. No one with all three doses of the vaccine is currently on an ECMO machine. Of the patients on ECMO machines, 43 (91 percent) are unvaccinated, while only two have received the first two shots.
ECMO machines are a very limited resource that require a large number of personnel, placing a heavy load on the system and often requiring the closing or restricting of the number of beds in other hospital units. A significant number of the cases attached to ECMO machines are unvaccinated young people, which has provoked criticism and anger among medical personnel – some of whom have termed their patients “COVID fools.” (...)
According to Health Ministry data for the past week, the death rate among unvaccinated people over the age of 60 stood at 6.3 per 100,000, compared to 1.3 for double-vaccinated people and 0.1 for those who received a booster shot.
For those aged under 60, there were 0.04 deaths per 100,000 for the unvaccinated, 0.02 for double-vaccinated people, 0.01 for those who received a booster shot – meaning that the vaccine “absolutely” has a significant impact on mortality, Leshem said.

Kako prenosi portal Glas Šumadije , do sada je trećom dozom imunizovano 18.217 građana Kragujevca, odnosno 10,31 posto od ukupne populacije.
Najveći broj se odlučio  za Sinofarm – 11.714, potom Fajzer – 4.923, a Sputnjik je kao treću dozu primilo 1.576 ljudi.
Cepivo „Astrazeneka“ kao buster dozu primilo je osmoro Kragujevčana.

Vakcina za sve tri doze se daje na punktu u ambulanti na Novom naselju i TC "Promenada". Građanima su na raspolaganju Fajzerova i Sinofarmova vakcina. 

Na vakcinalnom punktu u Kragujevcu nema vakcine Sputnjik koja bi se se davala građanima kao treća doza, pa se mnogi opredeljuju da umesto nje prime Fajzer kao buster dozu, rečeno je Beti u Domu zdravlja.
Portparolka Doma zdravlja Danijela Petrović je rekla da se normalizacija snabdevanja vakcinom Sputnjik V za buster dozu očekuje za dve sedmice.
Ona je rekla da ruske vakcine ima dovoljno za prvu dozu za građane koji su zakazali imunizaciju, kao i za revakcinaciju.

China Vaccine Diplomacy Wavers as Nations Seek Western Shots
In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.
But many governments that once relied on vaccines from Sinovac Biotech Ltd. or Sinopharm Group Co Ltd. are now turning to options from the U.S. and Europe instead, as concerns mount about Chinese vaccines’ efficacy against the delta strain and the Western stranglehold on mRNA supplies grows looser. That preference may already be showing up in China’s customs data, where exports of human vaccines dropped 21% in August to $1.96 billion from $2.48 billion in July, after rising steadily since Dec. 2020.
“Basically people took what they could get” when Covid vaccines first became available, said Nicholas Thomas, an associate professor at the City University of Hong Kong who has edited several books on foreign policy and public health.
“But as this has gone on, general populations -- rather than just medical practitioners -- have become more educated about the differences,” he said. “They have realized that not all vaccines are equal in terms of protection.”
 

 
This shift played out during Thailand’s deadly outbreak earlier this year. As cases surged and Southeast Asia emerged as the new epicenter of the pandemic, the nation desperately tried to purchase vaccines. Only one supplier came through in time: China’s Sinovac.
The shots allowed the country of 70 million to begin its inoculation campaign earlier than hoped, but Thailand soon confronted a challenge now faced by lawmakers across the developing world.
The efficacy of China’s inactivated vaccines ranges from about 50% to 80% in clinical trials. But they are less potent than mRNA vaccines and questions are mounting about their effectiveness against the highly transmissible delta variant. As a result, the Thai government became the first in the world to offer an AstraZeneca Plc shot to people who had already received a jab or even two of Sinovac. While it is not an mRNA, Thai studies showed the Cambridge, U.K.-based company’s viral vector vaccine is potent as a booster to the Chinese shot, and that Pfizer’s dose was found to be even more effective.
But many Thais soon expressed a strong preference for Western shots -- even protesting to demand them -- and the country’s opposition began lambasting the government for its reliance on China. Thailand halted orders of Sinovac and began buying more Western vaccines.
“I’m not anti-Sinovac,” said Chaowat Sittisak, a 29-year-old teacher in northern Thailand who got a first dose of Sinovac but ordered a second Moderna shot from a private hospital. “If the world only had one vaccine and it’s Sinovac, I’d get it. But we have so many other choices. And I want whatever is best.”
Many governments that once relied on Chinese shots are now ordering or seeking donations of mRNA vaccines instead. The swing away from China is likely to accelerate as U.S. President Joe Biden promises to donate 1.1 billion mRNA shots, Europe pledges hundreds of millions of vaccines and India prepares to once again export AstraZeneca vaccines after curtailing shipments following its deadly second wave. In addition to availability and efficacy, freedom of movement may also be motivating the shift: Recipients of Chinese vaccines can’t travel to some locations, such as Singapore.
Vaccine Exports
In a written reply to Bloomberg, Sinovac said its CoronaVac shot has been effective at preventing hospitalization, intensive care admissions and deaths throughout the pandemic. A spokesperson said some countries first rolled out Sinovac to the elderly, who are more likely to be hospitalized with Covid-19, while younger populations received different vaccines later, “and this should be factored in the evaluation of CoronaVac’s effectiveness.”
Many countries, including Thailand, have “purchased vaccines from multiple suppliers in order to maximize the number of doses available for their population,” the company said.
As things stand, the list of places shifting away from Chinese vaccines -- or augmenting them with Western boosters -- includes Singapore, Turkey and the United Arab Emirates. In China’s own territory of Hong Kong, which has long offered residents a choice between BioNTech and Sinovac, health officials are now testing whether the Chinese shot will perform better when paired with a western booster.
Even in Pakistan, an all-weather ally of Beijing that’s used Chinese shots for 84% of its vaccination drive, some are going out of their way to find Western jabs: Muhammad Kashif, a 41-year-old motorcycle delivery rider in Karachi, felt lucky to find a rare dose of the Moderna vaccine at a crowded inoculation center where later arrivals were forced to get Sinovac.
“I thought that this is American, they must have made it after a lot of high-level research,” Kashif said. “I feel delighted I was able to get it. I feel it’s much safer.”
 

 
While Sinovac allowed Thailand to start its rollout earlier than planned, the 6 million doses arriving in October will be the last shipment. In 2022, at least three quarters of the government’s orders will also come from Astra and Pfizer.
Moves like Thailand’s represent a blow to China’s vaccine diplomacy ambitions. Nevertheless, governments face a tricky balance between wanting to protect the public and maintaining good relations with China. The Thai Health Ministry has been careful to say that while it has no plans to order more Sinovac, it isn’t suggesting the shots aren’t effective.  
Chinese firms have exported some 884 million doses of its homegrown vaccines via mostly bilateral deals with places like Brazil and Indonesia. This week Chile started giving Sinovac shots to children as young as six, a strong endorsement of a shot that’s formed the backbone of their rollout. 
And there are still many parts of the world drastically short of vaccines. Some African nations, for instance, have barely started their inoculation drives after struggling to procure shots. Cote d’Ivoire, Burkina Faso and Kenya are all rolling out Chinese vacciness, and Beijing is a key supplier to the World Health Organization-backed Covax facility aimed at getting vaccines to the developing world. President Xi Jinping has pledged to export 2 billion doses this year, matching commitments by Group of Seven nations.
Various studies conducted around the world have shown the jabs to be effective at preventing serious illness and death. 
Yet China’s pharmaceutical firms -- which were initially less forthcoming than western companies in releasing clinical trial data -- have not released similarly conclusive studies that inactivated vaccines are effective against delta.
Over the coming year, policy makers may well continue turning away from the older technology of the inactivated Chinese vaccines, says Benjamin Cowling, a professor of epidemiology and biostatistics at the University of Hong Kong, who published a recent study in the Lancet showing the Pfizer vaccine generated 10 times more antibodies than Sinovac.
“If you’ve got some vaccines that are more effective than others, and the cost is roughly the same, then you’re going to get a better bang for the buck if you choose the more effective vaccines,” Cowling said. “But I still think that the supplies are limited, so it may not be as easy as saying, ‘We just want to order the Moderna vaccine,’ or whatever.”
‘Better Alternatives’
In Thailand, the opposition Move Forward party is now calling on the government to reveal the percentage of people who have only received the Sinovac shots.
“The government already knows that studies and research show inactivated virus vaccines are less effective against virus mutations when compared to mRNA-based vaccines,” said Wiroj Lakkhanaadisorn, an opposition lawmaker and a key critic of the government’s vaccine policies. “We should know the vaccination rate that excludes all two-dose Sinovac shots because the immunity may not be enough any more. Any regions that are ready can then reopen.”
Thailand’s health ministry didn’t respond to a request for comment.
Chaowat, the teacher, said he felt pressured to take the Sinovac shot because of his job but is hoping to get a Moderna shot in a month or two.
“The government is turning away from Sinovac because they have to push through with their reopening plan and they want to reduce vaccine hesitancy among people who don’t want Sinovac,” he said. “They’re turning to better alternatives.”

„Isto kao klasični turistički aranžman, samo što je tura od hotela do punkta za vakcinaciju na Beogradskom sajmu" - iako su iz zemlje Sputnjika V, Rusi dolaze na „švedski sto“ vakcina koje Srbija nudi 🧳https://t.co/FDiEE6N7MT

— BBC NEWS na srpskom (@bbcnasrpskom) September 30, 2021

rumbeando wrote:Bloomberg tvrdi da globalno opada interesovanje za kineske vakcine.

Covid pill works against all variants including Delta, manufacturer says https://t.co/00aw2aF1j3

— The Independent (@Independent) September 30, 2021

Merck said earlier this year that a small, mid-stage trial found that after five days of molnupiravir treatment, none of the patients taking various doses of the drug tested positive for the virus, while 24 per cent of placebo patients had detectable levels of the virus.

Merck is currently conducting two Phase III trials of the antiviral it is developing with Ridgeback Biotherapeutics — one to treat Covid-19 and another to prevent it.

The trial enrolled non-hospitalised Covid-19 patients who have had symptoms for no more than five days and are at risk for severe disease. The Phase III treatment study is expected to finish in early November, Mr [Jay] Grobler [head of infectious disease and vaccines at Merck] said.

Talason wrote:drugo, isto važno

stalno mi se žale iz raznih fabrika automobila da moraju da prekinu proizvodnju zato što im nedostaju čipovi

ja naivno, glupo pitam - pa dobro gde su svi ti čipovi, kako ih nema ni za koga

direktor jedne od većih fabrika me samo tužno pogleda i kroz stisnute zube čih samo neki pfizzz

ja kao molim ne razumem

pa celokupni kapaciteti idu za fajzer

aaa, pa da

Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorization for the pill as soon as possible and to submit applications to regulatory agencies worldwide. Due to the positive results, the Phase 3 trial is being stopped early at the recommendation of outside monitors.
"This is going to change the dialog around how to manage COVID-19," Robert Davis, Merck's chief executive officer, told Reuters.
...
Planned interim analysis of 775 patients in Merck's study found that 7.3% of those given molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, but there were eight deaths of placebo patients.

Ковид-анализа: Невакцинирани се 77 отсто од заразените, 79 отсто од хоспитализираните и 85 отсто од починатите
Министерството за здравство ги анализира податоците за бројот на заразени, хоспитализираните и починатите од ковид-19 во периодот од 6 август до 30 септември
Меѓу заразените, 23 отсто се вакцинирани, а кај починатите тој процент е 15
Во периодот од 6 август до 30 септември во државава се регистрирани 35 531 граѓанин позитивни на коронавирусот, објави денеска Министерството за здравство.  Од нив, 23 отсто, односно 8 233 лица, биле целосно вакцинирани.
За вакцинирани се сметаат лицата со две дози со поминати најмалку 14 дена од примање на втората доза вакцина.
Според статистиката за изминативе недели, 27 298 граѓани, односно 77 проценти од позитивните не биле вакцинирани, наведува Министерството кое денеска објави анализа за речиси два месеца.
И кај хоспитализираните, 79 отсто се невакцинирани, додека  21 процент од сите кои во овој период биле примени на болничко лекување, се целосно вакцинирани.
Во однос на смртноста, во период од 6 август до 30 септември  на територија на државата починале 1 162 лица со ковид-19. Од нив 987 пациенти не биле вакцинирани, а 15 отсто (175 лица) биле вакцинирани.
Од Министерството за здравство велат дека вакцинираните кои починале имале повеќе комбинирани хронични заболувања, а биле вакцинирани со сите типови вакцини кои ги има на располагање кај нас, како и пациенти кои се вакцинирале во странство со вакцини на „Модерна“ и „Џонсон“.
Во споредба со анализата објавеа минатата недела, бројката на заразени, хоспитализирани и починати кои биле вакцинирани бележи пораст од еден процент.

North Macedonia
People fully vaccinated against COVID-19 724,835

Попишани се 1 832 696 лица, 568 175 домаќинства и 837 255 станови, соопшти вечерва директорот на Државниот завод за статистика (ДЗС), Апостол Симовски.

Broj doza: 6.497.670 – prva doza 3.040.293, druga doza 2.901.882, treća doza 555.495
Državljani RS – prva doza 2.870.854, druga doza 2.750.459, treća doza 552.760
Strani državljani sa boravkom u RS – prva doza 10.281, druga doza 9.399, treća doza 852
Strani državljani bez boravka u RS – prva doza 159.158, druga doza 142.024, treća doza 1.883
ažurirano 30.09.2021

Broj doza: 6.371.972 – prva doza 3.014.528, druga doza 2.876.832, treća doza 480.612
Državljani RS – prva doza 2.845.970, druga doza 2.726.425, treća doza 478.646
Strani državljani sa boravkom u RS – prva doza 10.125, druga doza 9.274, treća doza 761
Strani državljani bez boravka u RS – prva doza 158.433, druga doza 141.133, treća doza 1.205
ažurirano 23.09.2021

Erős Pista wrote:

Talason wrote:drugo, isto važno

stalno mi se žale iz raznih fabrika automobila da moraju da prekinu proizvodnju zato što im nedostaju čipovi

ja naivno, glupo pitam - pa dobro gde su svi ti čipovi, kako ih nema ni za koga

direktor jedne od većih fabrika me samo tužno pogleda i kroz stisnute zube čih samo neki pfizzz

ja kao molim ne razumem

pa celokupni kapaciteti idu za fajzer

aaa, pa da

Pametnom dosta.

https://t.co/lLeHPXpDrJ

— José Morgado (@josemorgado) October 1, 2021